mme_fb_event_banner_tangent_dj

Patient Experience: Living with two rare diseases

March 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wyburn-Mason Syndrome, acromegaly, feature, patient experience, pharma, rare disease

Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. …

shutterstock_212432119

Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure

March 18, 2019
Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure

UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …

NHS struggles to meet targets as more demand for services grows

March 18, 2019
Sales and Marketing A&E, NHS, hospitals

The NHS is struggling to meet targets as the health service is being used by more patients than ever before, …

NICE to set out new opioid prescription guidelines for GPs

March 18, 2019
Sales and Marketing GPs, NICE, addiction, addictive drugs, opioids, prescription drugs, withdrawal

NICE is set to develop new guidelines for GPs and healthcare professionals setting out rules for doctors regarding opioids and …

heart-2372134_640

Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019
Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …

920x920

Purdue Pharma vow not to profit from fast tracked opioid overdose antidote

March 18, 2019
Sales and Marketing FDA, OxyContin, Purdue Pharma, nalmefene hydrochloride, opioids

The FDA has granted OxyContin drugmaker Purdue Pharma, fast track designation for opioid overdose antidote nalmefene hydrochloride (HCl) injection. However, …

mr058666-web

Merck KGaA enters drug discovery partnership with AI firm Itkos

March 15, 2019
Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma

Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …

norman_sharpless_official_photo

National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …

richard-francis-big-image_0

Sandoz CEO Richard Francis to step down

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …

images

Roche scores two EU approvals in haemophilia and rare autoimmune disease

March 15, 2019
Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases

The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …

merckwindow_web

MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer

March 15, 2019
Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Acadia Pharmaceuticals, FDA, Sandoz, brexit, genomics, pharma, pharmacovigilance, top 10

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …

ianread

Pfizer CEO Ian Read’s pay packet cut from $27.9m to $19.5m

March 15, 2019
Medical Communications CEO, Ian Read, Pfizer, compensation, pay packet, salary

Ian Read has seen his total compensation cut from a sum of $27.9 million in 2018 to $19.5 million this …

roche_dark_0

Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors

March 14, 2019
Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma

Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …

celgene_building

Celgene’s Abraxane combo flops in phase 3 cancer trials

March 14, 2019
Research and Development Abraxane, Celgene, clinical trials, pharma, trials

Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …

ent-cholesterol_molecule_spacefill

New class of drugs offer alternative to statins

March 14, 2019
Research and Development cholesterol, health, imperial college london, research, statins

A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study …

richard-francis-big-image

Sandoz CEO Richard Francis to step down

March 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …

Califonia court rules J&J must pay woman with mesothelioma $29 million

March 14, 2019
Medical Communications, Sales and Marketing

A California jury has ordered American healthcare conglomerate Johnson & Johnson to pay more than $29 million to a woman …

norman_sharpless_official_photo

National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner

March 13, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Ned Sharpless, Scott Gottlieb, appointment, pharma

Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …

janssen_latest_logo_on_sign_closer

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019
Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …

The Gateway to Local Adoption Series

Latest content